Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 43.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 634,331 shares of the biotechnology company’s stock after selling 495,721 shares during the period. Los Angeles Capital Management LLC’s holdings in Ironwood Pharmaceuticals were worth $2,138,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. LSV Asset Management acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $30,000. Simplify Asset Management Inc. acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $37,000. MQS Management LLC acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $42,000. Calamos Advisors LLC acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $49,000. Finally, Integrated Wealth Concepts LLC grew its holdings in Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares in the last quarter.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the completion of the transaction, the director directly owned 9,188,635 shares of the company’s stock, valued at $28,025,336.75. This trade represents a 42.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.30% of the stock is currently owned by corporate insiders.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $3.22 on Wednesday. The firm has a market cap of $525.05 million, a P/E ratio of 5.37 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.58 and a 1-year high of $5.78. The firm has a fifty day moving average of $3.82 and a two-hundred day moving average of $3.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on IRWD. Jefferies Financial Group reaffirmed a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Citizens Jmp raised their price target on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.